Liu et al, introduced a FOS inhibitor (T-5224) into cancer cell lines, inhibiting the expression of GABPB, suppressing the GABPB/mutant TERT cascade, reducing the control of survivin, activating TRAIL-R2 (tumor necrosis factor-related apoptosis-inducing ligand receptor 2), and resulting in cancer cell apoptosis.43 These findings, as well as other promising studies such as targeting telomerase,46,47 provide hope for a potential future therapeutic strategy that warrants future clinical investigation. Here, BIRC5 is linked to cancer.